Check 35,000+ stocks against 26 valuation models and 37 quality factors

Lee’s Pharmaceutical Holdings Ltd (0950) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of Lee’s Pharmaceutical Holdings Ltd HK$3.13, price HK$1.17, upside +167.5%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Healthcare · HK · ISIN KYG5438W1116

LS Thin data Sep 27, 2026

Lee’s Pharmaceutical Holdings Ltd

0950 · HK

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value HK$3.13 · Strongly undervalued (+167.5%)

!Quality 49/100

!Mixed Growth (revenue 5y +3.4 %/yr)

!Thin margins · 6.4% net margin (TTM)

✓Low debt · generates free cash flow

✓3.8% dividend yield · Well covered

!Mixed vs. peers (8/14)

!Narrow moat 28/100

!Evidence only low, so the estimate is less certain

!Weak on past: 12 out of 100

26 models, one by oneBear HK$2.28 to bull HK$4.07 Growth analysisrevenue history, year by year Quality 49/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Lee’s Pharmaceutical Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.9918 – HK$4.51 · fair‑value band HK$2.28 – HK$4.07 · the HK$1.17 price screens below the HK$3.13 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Lee’s Pharmaceutical Holdings in your weekly email

Every Wednesday you see whether Lee’s Pharmaceutical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

Stock analysis

Lee’s Pharmaceutical Holdings Ltd (0950) currently trades at HK$1.17, while our model-based Fair Value estimate is HK$3.13, implying the stock looks roughly 62.6% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$3.31 per share, and 23 of the 24 models we run sit above the HK$1.17 price.

Bear case: the Economic Profit group reads lowest at HK$1.32, and 1 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$2.28 (bear) to HK$4.07 (bull), the price of HK$1.17 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lee’s Pharmaceutical Holdings Ltd reported revenue of HK$1.4B in FY2025 versus HK$1.3B in FY2021, a compound +3.2%/yr. Reported net income was HK$91.9M in FY2025, compounding −53.6%/yr from FY2021.

Key figures

Market cap HK$689M (≈ $87.8M) · P/E ratio 6.5 · P/S ratio 0.42 · EPS (TTM) HK$0.1100 · Dividend yield 3.8% · Net margin 6.4% · Return on equity 2.9% · Return on assets (EBIT) 13.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 168%, 0950 screens cheaper than that median.

Fair Value models

Bear HK$2.28 Fair Value HK$3.13 Bull HK$4.07

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0486 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$2.22 HK$3.31 HK$4.90 80

Growth DCF HK$2.18 HK$3.11 HK$4.36 79

Owner Earnings HK$0.8500 HK$1.09 HK$1.44 78

All 24 models by family

DCF Models

FCF DCF HK$2.22 HK$3.31 HK$4.90 80

Owner Earnings HK$0.8500 HK$1.09 HK$1.44 78

5Y Revenue Exit HK$1.94 HK$2.90 HK$4.20 72

5Y EBITDA Exit HK$3.50 HK$6.16 HK$9.55 74

5Y P/E Exit HK$2.56 HK$4.20 HK$6.10 70

10Y Revenue Exit HK$1.99 HK$2.87 HK$4.18 67

10Y EBITDA Exit HK$2.92 HK$4.92 HK$8.05 67

10Y P/E Exit HK$2.38 HK$3.69 HK$5.55 63

Earnings-Based

Graham-Dodd HK$1.06 HK$5.14 HK$7.07 64

Lynch FV HK$1.37 HK$1.96 HK$2.55 61

PEG = 1.0 HK$1.37 HK$1.96 HK$2.55 57

EPV HK$1.23 HK$1.32 HK$1.40 74

Multiples

P/E Multiple HK$2.58 HK$3.43 HK$4.29 63

P/S Multiple HK$1.99 HK$2.65 HK$3.32 58

P/B Multiple HK$1.99 HK$2.65 HK$3.32 55

EV/EBIT HK$2.32 HK$2.94 HK$3.56 66

EV/EBITDA HK$4.76 HK$6.20 HK$7.64 67

EV/Revenue HK$1.78 HK$2.35 HK$2.92 54

Asset-Based

NCAV (Graham) HK$1.74 HK$2.33 HK$3.47 54

Growth DCF

Growth DCF HK$2.18 HK$3.11 HK$4.36 79

Rev-Margin DCF HK$1.94 HK$2.89 HK$4.15 72

Economic Profit

Residual Income HK$2.36 HK$2.26 HK$2.29 76

ROIC Compounder HK$1.23 HK$1.32 HK$1.40 72

Growth Earnings

Growth-Adj P/E HK$2.19 HK$3.13 HK$4.07 67

Open the full fair value analysis →

Notify me when 0950 reaches fair value

Put 0950 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 51 · Market factors (momentum, volatility) 34

Profitability 31

Margins and returns on capital today

Quality Growth 18

Are margins and returns improving?

Cashflow 55

Earnings quality: real cash, not paper profit

Fin. Strength 65

Balance sheet, leverage, solvency risk

Investment 58

Disciplined investing over empire-building

Low Volatility 61

Calm price path (market factor)

Momentum 32

Price trend over the last 3–12 months (market factor)

52W Momentum 5

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 60/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+2.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.4%

Start year 2020 (pandemic). Over 10 years: +4.5% a year

Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+22.8%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

≈ −15.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year−18.8%

Dividend (yield on the price)3.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−6.6% vs −8.8%, steady

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 6%

Start year 2020 (pandemic)

⚠ Rate on operating basis: 2025 sits 79% above its own trend.

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−7.6%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −9.5% a year for the price.

Watch 0950, get fair value alerts →

Compare Lee’s Pharmaceutical Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 622 stocks

Beats the industry median on 8/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 49 · Below median

Fair Value upside +167.5% · Top 25%

Profitability

Return on equity (TTM) 2.9% · Below median

Return on assets 2.3% · Below median

Net margin (TTM) 6.4% · Below median

Operating margin (TTM) 5.9% · Below median

Growth and dividend

Revenue growth −0.1% · Below median

Dividend yield (TTM) 3.8% · Top 25%

Balance sheet

Debt / equity 0.04× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 6.5× · Cheapest 25%

P/B 0.34× · Cheapest 25%

P/S (TTM) 0.48× · Cheapest 25%

P/FCF 6.8× · Cheapest 25%

EV/EBITDA 2.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 16

FUTURE (revenue growth)0 · sector 18

PAST (return on equity)12 · sector 26

HEALTH (low debt)98 · sector 96

DIVIDEND (yield)77 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€135.00	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$71.05	$110.50	+56%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lee’s Pharmaceutical Holdings Ltd · Fair Value
HK$3.13 +63%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0950" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Lee’s Pharmaceutical Holdings Ltd · Fair Value</span><br><b style="font-size:20px">HK$3.13</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+63%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Lee’s Pharmaceutical Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0950

Frequently asked questions

Is Lee’s Pharmaceutical Holdings Ltd (0950) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$3.13 versus a price of HK$1.17, about +168% upside (undervalued).

What is the fair value of 0950?

Our model-based fair value for Lee’s Pharmaceutical Holdings Ltd is HK$3.13 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$1.17.

What is the quality score of 0950?

Lee’s Pharmaceutical Holdings Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Lee’s Pharmaceutical Holdings Ltd (0950)?

Our model-based price target is the fair value of HK$3.13 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$2.28, optimistic scenario HK$4.07. It is a calculation from audited fundamentals, not an analyst target.

What is the Lee’s Pharmaceutical Holdings Ltd stock forecast for 2026?

Our models put fair value at HK$3.13, about +168% upside versus a price of HK$1.17 (undervalued). Cautious scenario HK$2.28, optimistic scenario HK$4.07. The calculation is refreshed regularly with new filings.

What is the revenue of Lee’s Pharmaceutical Holdings Ltd (0950)?

Lee’s Pharmaceutical Holdings Ltd reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Sep 27, 2026).

Does Lee’s Pharmaceutical Holdings Ltd pay a dividend?

Lee’s Pharmaceutical Holdings Ltd currently shows a dividend yield of about 3.85% relative to its recent price (as of Sep 27, 2026).

What growth is priced into Lee’s Pharmaceutical Holdings Ltd (0950)?

For today's price to be fair in a discounted-cash-flow model, Lee’s Pharmaceutical Holdings Ltd would have to grow free cash flow by -7.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 0950 use?

Our models discount Lee’s Pharmaceutical Holdings Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.56, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Lee’s Pharmaceutical Holdings Ltd that is -7.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.

How much growth has Lee’s Pharmaceutical Holdings Ltd (0950) delivered so far?

Over the past 5 years revenue at Lee’s Pharmaceutical Holdings Ltd grew +3.4 % a year. The price currently implies -7.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Lee’s Pharmaceutical Holdings Ltd (0950) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Lee’s Pharmaceutical Holdings Ltd (-7.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Lee’s Pharmaceutical Holdings Ltd (0950)?

The free-cash-flow yield on the price is 14.71 %: that much free cash flow Lee’s Pharmaceutical Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Lee’s Pharmaceutical Holdings Ltd (0950)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lee’s Pharmaceutical Holdings Ltd it is HK$3.13 per share (as of Sep 27, 2026), against a price of HK$1.17. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Lee’s Pharmaceutical Holdings Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 0950 trades below its calculated fair value: price HK$1.17, fair value HK$3.13, a gap of about +168% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0950?

No. The price is what the market pays today (HK$1.17); the fair value is what the company's own numbers justify (HK$3.13). For Lee’s Pharmaceutical Holdings Ltd the two are HK$1.96 per share apart. That gap is exactly why we show both numbers side by side.

How much is Lee’s Pharmaceutical Holdings Ltd worth?

The market values Lee’s Pharmaceutical Holdings Ltd at about HK$689M (market capitalisation, as of Sep 27, 2026). Per share that is HK$1.17; our models calculate a fair value of HK$3.13 per share.

What do the bullish and bearish scenarios say about 0950?

Our models span a range for Lee’s Pharmaceutical Holdings Ltd: cautious scenario HK$2.28, base HK$3.13, optimistic HK$4.07 per share (as of Sep 27, 2026, price HK$1.17). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0950?

Lee’s Pharmaceutical Holdings Ltd trades at a price-to-earnings ratio of 6.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.13 is built from several models across several years. Other multiples: P/B 0.3, P/S 0.5, EV/EBITDA 2.1.

How solid is the balance sheet of Lee’s Pharmaceutical Holdings Ltd (0950)?

Balance-sheet figures for Lee’s Pharmaceutical Holdings Ltd (as of Sep 27, 2026): return on equity 2.9%, debt of 0.04 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.

How far is 0950 from its 52-week high?

Lee’s Pharmaceutical Holdings Ltd trades at HK$1.17, about 50% below its 52-week high of HK$2.33 and 14% above the low of HK$1.03 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.13 is for.

Which stocks are comparable to Lee’s Pharmaceutical Holdings Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Lee’s Pharmaceutical Holdings Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$1.17, calculated fair value HK$3.13 (+168%), Quality Score 49/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0950 calculated?

We run Lee’s Pharmaceutical Holdings Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$3.13, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.9 % above its aggregate fair value. Lee’s Pharmaceutical Holdings Ltd currently trades 63 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Lee’s Pharmaceutical Holdings Ltd (0950)?

The closing price on Sep 29, 2026 was HK$1.17. Our model-based fair value is HK$3.13, about +168% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Lee’s Pharmaceutical Holdings Ltd right now?

The price is below even our cautious bear case (HK$2.28). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality.

Where does the earnings growth of Lee’s Pharmaceutical Holdings Ltd (0950) come from?

Earnings per share at Lee’s Pharmaceutical Holdings Ltd grew −12.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.5 %, EBIT margin −15.7 %, tax rate −1.0 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Lee’s Pharmaceutical Holdings Ltd

How large is the market capitalisation of Lee’s Pharmaceutical Holdings Ltd (0950)?

The market capitalisation of Lee’s Pharmaceutical Holdings Ltd is HK$689M (≈ $87.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Lee’s Pharmaceutical Holdings Ltd (0950)?

The price-to-sales ratio of Lee’s Pharmaceutical Holdings Ltd is 0.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Lee’s Pharmaceutical Holdings Ltd (0950)?

Earnings per share at Lee’s Pharmaceutical Holdings Ltd are HK$0.1100 (price ÷ EPS = P/E 6.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Lee’s Pharmaceutical Holdings Ltd (0950)?

The dividend yield of Lee’s Pharmaceutical Holdings Ltd is 3.8% (payout 40.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Lee’s Pharmaceutical Holdings Ltd (0950)?

The net margin of Lee’s Pharmaceutical Holdings Ltd is 6.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Lee’s Pharmaceutical Holdings Ltd (0950)?

The return on equity (ROE) of Lee’s Pharmaceutical Holdings Ltd is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Lee’s Pharmaceutical Holdings Ltd (0950)?

On an EBIT basis the return on assets of Lee’s Pharmaceutical Holdings Ltd is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Lee’s Pharmaceutical Holdings Ltd (0950)?

The operating margin of Lee’s Pharmaceutical Holdings Ltd is 5.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Lee’s Pharmaceutical Holdings Ltd (0950)?

Revenue at Lee’s Pharmaceutical Holdings Ltd is growing −0.1% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Lee’s Pharmaceutical Holdings Ltd (0950)?

Earnings per share at Lee’s Pharmaceutical Holdings Ltd are growing −19.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Lee’s Pharmaceutical Holdings Ltd (0950) hold?

Lee’s Pharmaceutical Holdings Ltd holds more cash than debt, HK$39.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Lee’s Pharmaceutical Holdings Ltd in the live analysis

One click puts Lee’s Pharmaceutical Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.